Concerns Rise as FDA Criticizes uniQure's AMT-130 Data and Seeks Accountability

Concerns Over uniQure's AMT-130 Data and FDA's Public Critique

In a dramatic turn of events, the U.S. Food and Drug Administration (FDA) has sharply criticized uniQure N.V., a biotechnology company known for its gene therapies, particularly AMT-130, aimed at treating Huntington’s disease. The scrutiny has intensified following the firm's significant drop in stock value amid a pending securities class action lawsuit initiated by investors.

As of March 2026, national shareholder rights law firm Hagens Berman has ramped up its investigation into uniQure after the FDA's unprecedented public condemnation of the data supporting the AMT-130 therapy. According to reports from the Wall Street Journal, the FDA highlighted severe problems with the clinical data submitted by uniQure, suggesting it was not only flawed but misleading. In a stark declaration, a senior FDA official stated that the data did not meet the standards necessary for approval. Furthermore, it was emphasized that uniQure had “lied” regarding the nature of its interactions with the FDA about how the therapy compared with placebo treatments.

The AMT-130 candidate has been positioned as a potential breakthrough treatment for Huntington’s disease, a notoriously challenging condition that leads to the progressive degeneration of brain cells. However, recent disclosures raised doubts about the robustness of the Phase I/II trials. The FDA officials expressed concerns that the design of uniQure’s Pivotal Study had not received complete approval, suggesting that investors may have been misled about the readiness and compliance of these studies with regulatory expectations. This controversy erupted after a series of reports dating back to November 2025, which have seen uniQure’s stock plummet by nearly 84%.

The primary allegations made in the securities class action include claims that uniQure failed to disclose critical information regarding the status and design of their pivotal studies on AMT-130. Investors who purchased shares between September 24 and October 31, 2025, now find themselves grappling with substantial losses as the price of the stock plunged following revelations regarding the integrity of the drug’s clinical data.

The firm’s lead partner, Reed Kathrein, noted that the critical nature of their investigation revolves around the differences between the statements made by uniQure and the details that have emerged from discussions with the FDA. Investors are being urged to share any experiences or knowledge related to the case as the investigation unfolds.

In tandem with the decline in share price, the feedback from the FDA has raised several questions about the ethical considerations and corporate accountability in drug development. The scientific disagreements that initially arose over how to study the therapeutic effects of AMT-130 evolved into what can only be described as a public relations crisis for uniQure.

Hagens Berman's unyielding focus on protecting the rights of investors aligns with their broader mission of ensuring that corporations uphold their responsibilities. As the firm moves forward, they will continue to scrutinize uniQure’s practices while advocating for transparency in the complex landscape of biotech investment.

The situation remains delicate, as the outcome of this saga could set precedents for future biotech companies. Investors are advised to remain vigilant about the clinical data their investments are based on, and the importance of regulatory approval processes. If you have significant financial involvement with uniQure, reaching out to Hagens Berman could be a prudent step amid this unfolding dispute.

The emphasis on accountability is not just confined to uniQure; it speaks to a wider need for ethical dynamics within the pharmaceutical industry. The complexities of clinical trials must be communicated clearly to investors, as they play a fundamental role in determining the future of drug therapies. As this case progresses, the implications could reverberate far beyond uniQure and its stakeholders, potentially reshaping the landscape of investor relations within the biotech sector.